ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EDAP EDAP TMS SA

5.20
0.215 (4.31%)
Last Updated: 16:25:29
Delayed by 15 minutes
Share Name Share Symbol Market Type
EDAP TMS SA NASDAQ:EDAP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.215 4.31% 5.20 5.13 5.20 5.20 5.00 5.108 1,157 16:25:29

INVESTOR ALERT: Class Action Lawsuit Against EDAP TMS S.A. Filed By Glancy Binkow & Goldberg LLP

12/08/2014 3:32pm

Business Wire


EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more EDAP TMS Charts.

Glancy Binkow & Goldberg LLP, representing investors of EDAP TMS S.A. (“EDAP” or the “Company”) (NASDAQ:EDAP), has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of a class (the “Class”) comprising purchasers of the Company’s securities between February 1, 2013 and July 30, 2014, inclusive (the "Class Period").

Please contact Casey Sadler at (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

EDAP, through its subsidiaries, develops, produces and markets minimally invasive medical devices for the treatment of urological diseases. The Company offers the Ablatherm-HIFU device for the treatment of organ-confined prostate cancer. The Complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the efficacy and safety of its Ablatherm trials by relying on cross-study comparisons rather than a head-to-head trial; (ii) the study’s survival endpoint was inappropriate for the patient population; and (iii) as a result of the above, the Company's statements about its business and operations were materially false and misleading at all relevant times.

On July 30, 2014, the FDA announced that the panel convened to review EDAP’s Ablatherm-HIFU submission unanimously found that EDAP had failed to demonstrate the efficacy of its product or that it had demonstrated that the benefits of the device outweighed its risk. Following this news, shares of EDAP declined more than 40 percent on July 31, 2014.

If you are a member of the Class described above, you may move the Court no later than October 3, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Binkow & Goldberg LLP, Los Angeles, CACasey Sadler(310) 201-9150(888) 773-9224shareholders@glancylaw.comwww.glancylaw.com

1 Year EDAP TMS Chart

1 Year EDAP TMS Chart

1 Month EDAP TMS Chart

1 Month EDAP TMS Chart